Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa Spain-based gl...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced that the European Unified Patent Court ("UPC") issued a...
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary ...
- Pharmanovia acquires 11 CNS brands, including Frisium® (clobazam) and Gardenal® (phenobarbital) - The portfolio is available in more than 60 mar...
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...
Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields...
Uniting the Global Supply Chain: CPHI Barcelona serves as a vital platform for unrivalled networks and access to the global supply chain. It provides unpa...
The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among childre...
Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and l...
The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a fou...
SpendEdge, a global leader in procurement market intelligence space recently connected with a large Europe-based pharma company focused on large and small ...
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age a...
© 2025 Biopharma Boardroom. All Rights Reserved.
